BACKGROUND: B cells are implicated in the pathogenesis of multiple sclerosis. A beneficial effect of B-cell depletion using rituximab has been shown, but the complete mechanism of action for this drug is unclear. OBJECTIVE: To determine the relationship between T and B cells and changes in cerebrospinal fluid (CSF) chemokine levels with rituximab, a monoclonal antibody that targets CD20. DESIGN: Phase 2 trial of rituximab as an add-on therapy. SETTING: The John L. Trotter Multiple Sclerosis Center, Washington University. Participants and Intervention Thirty subjects who had relapsing-remitting multiple sclerosis with clinical and magnetic resonance imaging activity despite treatment with an immunomodulatory drug received 4 weekly doses of rituximab (375 mg/m(2)). MAIN OUTCOME MEASURES: Lumbar puncture was performed before and after rituximab infusions in 26 subjects. Levels of B and T lymphocytes in the CSF were enumerated by flow cytometry, and chemoattractant levels were measured by enzyme-linked immunosorbent assay. RESULTS: After rituximab administration, CSF B-cell levels were decreased or undetectable in all subjects, and CSF T-cell levels were reduced in 21 subjects (81%). The mean reduction in CSF cellularity was 95% for B cells and 50% for T cells. After rituximab infusion, CSF CXCL13 and CCL19 levels decreased (P = .002 and P = .03, respectively). The proportional decline in CSF T-cell levels correlated with the proportional decrease in CXCL13 levels (r = 0.45; P = .03), suggesting a possible relationship. The CSF IgG index, IgG concentration, and oligoclonal band number were unchanged following treatment. CONCLUSIONS: In subjects with multiple sclerosis, B cells are critical for T-cell trafficking into the central nervous system and may alter the process by influencing chemokine production within the central nervous system.
BACKGROUND: B cells are implicated in the pathogenesis of multiple sclerosis. A beneficial effect of B-cell depletion using rituximab has been shown, but the complete mechanism of action for this drug is unclear. OBJECTIVE: To determine the relationship between T and B cells and changes in cerebrospinal fluid (CSF) chemokine levels with rituximab, a monoclonal antibody that targets CD20. DESIGN: Phase 2 trial of rituximab as an add-on therapy. SETTING: The John L. Trotter Multiple Sclerosis Center, Washington University. Participants and Intervention Thirty subjects who had relapsing-remitting multiple sclerosis with clinical and magnetic resonance imaging activity despite treatment with an immunomodulatory drug received 4 weekly doses of rituximab (375 mg/m(2)). MAIN OUTCOME MEASURES: Lumbar puncture was performed before and after rituximab infusions in 26 subjects. Levels of B and T lymphocytes in the CSF were enumerated by flow cytometry, and chemoattractant levels were measured by enzyme-linked immunosorbent assay. RESULTS: After rituximab administration, CSF B-cell levels were decreased or undetectable in all subjects, and CSF T-cell levels were reduced in 21 subjects (81%). The mean reduction in CSF cellularity was 95% for B cells and 50% for T cells. After rituximab infusion, CSFCXCL13 and CCL19 levels decreased (P = .002 and P = .03, respectively). The proportional decline in CSF T-cell levels correlated with the proportional decrease in CXCL13 levels (r = 0.45; P = .03), suggesting a possible relationship. The CSF IgG index, IgG concentration, and oligoclonal band number were unchanged following treatment. CONCLUSIONS: In subjects with multiple sclerosis, B cells are critical for T-cell trafficking into the central nervous system and may alter the process by influencing chemokine production within the central nervous system.
Authors: K M Ansel; V N Ngo; P L Hyman; S A Luther; R Förster; J D Sedgwick; J L Browning; M Lipp; J G Cyster Journal: Nature Date: 2000-07-20 Impact factor: 49.962
Authors: S Takemura; A Braun; C Crowson; P J Kurtin; R H Cofield; W M O'Fallon; J J Goronzy; C M Weyand Journal: J Immunol Date: 2001-07-15 Impact factor: 5.422
Authors: R T Naismith; L Piccio; J A Lyons; J Lauber; N T Tutlam; B J Parks; K Trinkaus; S K Song; A H Cross Journal: Neurology Date: 2010-06-08 Impact factor: 9.910
Authors: Richard M Ransohoff; Dorothy Schafer; Angela Vincent; Nathalie E Blachère; Amit Bar-Or Journal: Neurotherapeutics Date: 2015-10 Impact factor: 7.620
Authors: Ariele L Greenfield; Ravi Dandekar; Akshaya Ramesh; Erica L Eggers; Hao Wu; Sarah Laurent; William Harkin; Natalie S Pierson; Martin S Weber; Roland G Henry; Antje Bischof; Bruce Ac Cree; Stephen L Hauser; Michael R Wilson; H-Christian von Büdingen Journal: JCI Insight Date: 2019-03-21